High-throughput sequencing in vaccine research

1André M., Bridon J.M., Boussard E., Maisonneuve S., Lempereur L.: Next Generation Sequencing (NGS) for monitoring ultra-low level of genetic mutation as a quality control test of live poliovirus vaccine. Agence Nationale de Sécurité du Médicament et des Produits de Santé, Lyon, 2016, doi: 10.13140/RG.2.2.30124. 87687, https://www.researchgate.net/publication/311257310. André M. Bridon J.M. Boussard E. Maisonneuve S. Lempereur L. Next Generation Sequencing (NGS) for monitoring ultra-low level of genetic mutation as a quality control test of live poliovirus vaccine. Agence Nationale de Sécurité du Médicament et des Produits de Santé Lyon 2016 10.13140/RG.2.2.30124 87687 https://www.researchgate.net/publication/311257310Open DOISearch in Google Scholar

2Bennett S.T., Barnes C., Cox A., Davies L., Brown C.: Toward the 1,000 dollars human genome. Pharmacogenomics 2005, 6, 373–382, doi: 10.1517/14622416.6.4.373. Bennett S.T. Barnes C. Cox A. Davies L. Brown C. Toward the 1,000 dollars human genome Pharmacogenomics 2005 6 373 382 10.1517/14622416.6.4.37316004555Open DOISearch in Google Scholar

3Benson D., Karsch-Mizrachi I., Lipman D., Ostell J., Wheeler D., Genbank. Nucleic Acids Res, 35 (supplement 1), 2007, D21–D25, doi: 10.1093/nar/gkl986. Benson D. Karsch-Mizrachi I. Lipman D. Ostell J. Wheeler D. Genbank Nucleic Acids Res 35 supplement 1 2007 D21 D25 10.1093/nar/gkl986178124517202161Open DOISearch in Google Scholar

4Brown T.A.: Genomy. Wydawnictwo Naukowe PWN, Warsaw 2001, 36, pp. 60–70. Brown T.A. Genomy. Wydawnictwo Naukowe PWN Warsaw 2001 36, pp 60 70Search in Google Scholar

5Cafardi V., Telford J.L., Serruto D.: Bacterial Genomes and Vaccine Design. In: Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines, edited by D.R. Flower, Y. Perrie, Springer, London, 2013, pp. 13–37, doi: 10.1007/978-1-4614-5070-2. Cafardi V. Telford J.L. Serruto D. Bacterial Genomes and Vaccine Design In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines edited by Flower D.R. Perrie Y. Springer, London 2013 pp 13 37 10.1007/978-1-4614-5070-2Open DOISearch in Google Scholar

6Centlivre M., Combadière B.: New challenges in modern vaccinology. BMC Immunol 2015, 16, 18, doi: 10.1186/s12865-015-0075-2. Centlivre M. Combadière B. New challenges in modern vaccinology BMC Immunol 2015 16 18 10.1186/s12865-015-0075-2437437825879661Open DOISearch in Google Scholar

7Chandra Y.G., Lee J., Kong B. W.: Genome sequence comparison of two United States live attenuated vaccines of infectious laryngotracheitis virus (ILTV). Virus Genes 2012, 44, 470–474, doi: 10.1007/s11262-012-0728-7. Chandra Y.G. Lee J. Kong B. W. Genome sequence comparison of two United States live attenuated vaccines of infectious laryngotracheitis virus (ILTV) Virus Genes 2012 44 470 474 10.1007/s11262-012-0728-722382591Open DOISearch in Google Scholar

8Chen W.H., Strych U., Hotez P.J., Bottazzi M.E.: The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep 2020, 7, 61–64, doi:10.1007/s40475-020-00201-6. Chen W.H. Strych U. Hotez P.J. Bottazzi M.E. The SARS-CoV-2 Vaccine Pipeline: an Overview Curr Trop Med Rep 2020 7 61 64 10.1007/s40475-020-00201-6709494132219057Open DOISearch in Google Scholar

9Chwiałkowska K.: Pirosekwencjonowanie – sekwencjonowanie z wykorzystaniem kwantów światła (Pyrosequencing – sequencing by quanta of light) 2009. http://www.biotechnolog.pl/pirosekwencjonowanie-sekwencjonowanie-z-wykorzystaniem-kwantow-swiatla Chwiałkowska K. Pirosekwencjonowanie – sekwencjonowanie z wykorzystaniem kwantów światła (Pyrosequencing – sequencing by quanta of light) 2009 http://www.biotechnolog.pl/pirosekwencjonowanie-sekwencjonowanie-z-wykorzystaniem-kwantow-swiatlaSearch in Google Scholar

10Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W.: CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46, 1310–1314, doi: 10.1086/533467. Cooper C.L. Angel J.B. Seguin I. Davis H.L. Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years Clin Infect Dis 2008 46 1310 1314 10.1086/53346718444872Open DOISearch in Google Scholar

11Dhiman N., Smith D.I., Poland G.A.: Next-generation sequencing: a transformative tool for vaccinology. Expert Rev Vaccines 2009, 8, 963–967, doi: 10.1586/erv.09.67. Dhiman N. Smith D.I. Poland G.A. Next-generation sequencing: a transformative tool for vaccinology Expert Rev Vaccines 2009 8 963 967 10.1586/erv.09.67284313519627178Open DOISearch in Google Scholar

12Franzo G., Naylor C.J., Drigo M., Croville G., Ducatez M.F., Catelli E., Laconi A., Cecchinato M.: Subpopulations in aMPV vaccines are unlikely to be the only cause of reversion to virulence. Vaccine 2015, 33, 2438–2441, doi: 10.1016/j.vaccine.2015.03.092. Franzo G. Naylor C.J. Drigo M. Croville G. Ducatez M.F. Catelli E. Laconi A. Cecchinato M. Subpopulations in aMPV vaccines are unlikely to be the only cause of reversion to virulence Vaccine 2015 33 2438 2441 10.1016/j.vaccine.2015.03.09225865471Open DOISearch in Google Scholar

13Gardin Y., Palya V., Paniago M., Cazaban C., Alva B., Lozano F., El Attrache J., Ceva Animal Health: Gumboro Disease Special. The rational use of vaccines and vaccinations for real control of Gumboro disease. World Poultry 2014, April Supplement. Gardin Y. Palya V. Paniago M. Cazaban C. Alva B. Lozano F. El Attrache J. Ceva Animal Health Gumboro Disease Special. The rational use of vaccines and vaccinations for real control of Gumboro disease World Poultry 2014 April SupplementSearch in Google Scholar

14Gruca A.: Bioinformatyczne bazy danych (Bioinformatics databases – in Polish). Wydawnictwo PJWSTK, Warsaw, 2010. Gruca A. Bioinformatyczne bazy danych (Bioinformatics databases – in Polish) Wydawnictwo PJWSTK, Warsaw 2010Search in Google Scholar

15Guo N., Duan H., Kachko A., Krause B.W., Major M.E., Krause P.R.: Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display. EBioMedicine 2, 2015, 859–867, doi: 10.1016/j.ebiom.2015.06.021. Guo N. Duan H. Kachko A. Krause B.W. Major M.E. Krause P.R. Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display EBioMedicine 2 2015 859 867 10.1016/j.ebiom.2015.06.021456314126425692Open DOISearch in Google Scholar

16Hardwick S.A., Deveson I.W., Mercer T.R.: Reference standards for next-generation sequencing. Nat Rev Genet 2017, 18, 473–484, doi: 10.1038/nrg.2017.44. Hardwick S.A. Deveson I.W. Mercer T.R. Reference standards for next-generation sequencing Nat Rev Genet 2017 18 473 484 10.1038/nrg.2017.4428626224Open DOISearch in Google Scholar

17Hogrefe W., Hurban P.: A Next Generation Sequencing (NGS) Approach to Influenza Vaccine Development. Nature Res Custom Media 2020, https://www.nature.com/articles/d42473-020-00389-1 Hogrefe W. Hurban P. A Next Generation Sequencing (NGS) Approach to Influenza Vaccine Development Nature Res Custom Media 2020 https://www.nature.com/articles/d42473-020-00389-1Search in Google Scholar

18Illumina: Introduction to NGS http://www.illumina.com/technology/next-generation-sequencing.html. Illumina Introduction to NGS http://www.illumina.com/technology/next-generation-sequencing.htmlSearch in Google Scholar

19Jin Y., Yang H., Ji W., Wu W., Chen S., Zhang W., Duan G.: Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020, 12, 372, doi: 10.3390/v12040372. Jin Y. Yang H. Ji W. Wu W. Chen S. Zhang W. Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19 Viruses 2020 12 372 10.3390/v12040372723219832230900Open DOISearch in Google Scholar

20Kanampalliwar A.M., Soni R., Girdhar A., Tiwari A.: Reverse Vaccinology: Basics and Applications. J Vaccines Vaccin 2013, 4, 1–5, doi: 10.4172/2157-7560.1000194. Kanampalliwar A.M. Soni R. Girdhar A. Tiwari A. Reverse Vaccinology: Basics and Applications J Vaccines Vaccin 2013 4 1 5 10.4172/2157-7560.1000194Open DOISearch in Google Scholar

21Kaur S.P., Gupta V.: COVID-19 Vaccine: A comprehensive status report. Virus Res 2020, 288, 198114, doi: 10.1016/j.virusres.2020. 198114. Kaur S.P. Gupta V. COVID-19 Vaccine: A comprehensive status report Virus Res 2020 288 198114 10.1016/j.virusres.2020.198114742351032800805Open DOISearch in Google Scholar

22Khan A.S., Ng S.H.S., Vandeputte O., Aljanahi A., Deyati A., Cassart J.-P., Charlebois R.L., Taliaferro L.P.: A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection. mSphere 2017, 5, 1–19, doi: 10.1128/mSphere.00307-17. Khan A.S. Ng S.H.S. Vandeputte O. Aljanahi A. Deyati A. Cassart J.-P. Charlebois R.L. Taliaferro L.P. A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection mSphere 2017 5 1 19 10.1128/mSphere.00307-17559796928932815Open DOISearch in Google Scholar

23Koff W.C., Burton D.R., Johnson P.R., Walker B.D., King C.R., Nabel G.J., Ahmed R., Bhan M.K., Plotkin S.A: Accelerating Next Generation Vaccine Development for Global Disease Prevention. Science. 2013, 31, 340, 1232910, doi: 10.1126/science.1232910. Koff W.C. Burton D.R. Johnson P.R. Walker B.D. King C.R. Nabel G.J. Ahmed R. Bhan M.K. Plotkin S A Accelerating Next Generation Vaccine Development for Global Disease Prevention Science 2013 31 340 1232910 10.1126/science.1232910402624823723240Open DOISearch in Google Scholar

24Kuchar E.: Klasyfikacja i skład szczepionek (Classification and composition of vaccines – in Polish). https://www.mp.pl/pacjent/choroby-zakazne/szczepienia/158371,klasyfikacja-i-sklad-szczepionek. Kuchar E. Klasyfikacja i skład szczepionek (Classification and composition of vaccines – in Polish) https://www.mp.pl/pacjent/choroby-zakazne/szczepienia/158371,klasyfikacja-i-sklad-szczepionekSearch in Google Scholar

25Kulikova T., Akhtar R., Aldebert P., Althorpe N., Andersson M., Baldwin A., Bates K., Bhattacharyya S., Bower L., Browne P., Castro M., Cochrane G., Duggan K., Eberhardt R., Faruque N., Hoad G., Kanz C., Lee C., Leinonen R., Lin Q., Lombard V., Lopez R., Lorenc D., McWilliam H., Mukherjee G., Nardone F., Garcia Pastor M.P., Plaister S., Sobhany S., Stoehr P., Vaughan R., Wu D., Zhu W., Apweiler R.: EMBL nucleotide sequence database in 2006. Nucleic Acids Res 2007, 35, D16–D20, doi: 10.1093/nar/gkl913. Kulikova T. Akhtar R. Aldebert P. Althorpe N. Andersson M. Baldwin A. Bates K. Bhattacharyya S. Bower L. Browne P. Castro M. Cochrane G. Duggan K. Eberhardt R. Faruque N. Hoad G. Kanz C. Lee C. Leinonen R. Lin Q. Lombard V. Lopez R. Lorenc D. McWilliam H. Mukherjee G. Nardone F. Garcia Pastor M.P. Plaister S. Sobhany S. Stoehr P. Vaughan R. Wu D. Zhu W. Apweiler R. EMBL nucleotide sequence database in 2006 Nucleic Acids Res 2007 35 D16 D20 10.1093/nar/gkl913189731617148479Open DOISearch in Google Scholar

26Lee S.W., Markham P.F., Coppo M.J., Legione A.R., Markham J.F., Noormohammadi A.H., Browning G.F., Ficorilli N., Hartley C.A., Devlin J.M.: Attenuated vaccines can recombine to form virulent field viruses. Science 2012, 337, 188, doi: 10.1126/science.1217134. Lee S.W. Markham P.F. Coppo M.J. Legione A.R. Markham J.F. Noormohammadi A.H. Browning G.F. Ficorilli N. Hartley C.A. Devlin J.M. Attenuated vaccines can recombine to form virulent field viruses Science 2012 337 188 10.1126/science.121713422798607Open DOISearch in Google Scholar

27Listorti V., Laconi A., Catelli E., Cecchinato M., Lupini C., Naylor C.J.: Identification of IBV QX vaccine markers : Should vaccine acceptance by authorities require similar identifications for all live IBV vaccines? Vaccine 2017, 35, 5531–5534, doi: 10.1016/j.vaccine.2017.06.021. Listorti V. Laconi A. Catelli E. Cecchinato M. Lupini C. Naylor C.J. Identification of IBV QX vaccine markers : Should vaccine acceptance by authorities require similar identifications for all live IBV vaccines? Vaccine 2017 35 5531 5534 10.1016/j.vaccine.2017.06.02128917538Open DOISearch in Google Scholar

28Liu L., Zang Y., Jiang H., Xu F., Zhu C., Ge P., Liu X., Zhang Y., Jiang C.: Analysis of the genetic stability of the master virus seeds for live attenuated influenza vaccine production. Chin J Microbiol Immunol 2015, 35, 281–285, doi: 10.3760/cma.j.issn.0254-5101.2015.04.009, https://www.researchgate.net/publication/282376333_Analysis_of_the_genetic_stability_of_the_master_virus_seeds_for_live_attenuated_influenza_vaccine_production. Liu L. Zang Y. Jiang H. Xu F. Zhu C. Ge P. Liu X. Zhang Y. Jiang C. Analysis of the genetic stability of the master virus seeds for live attenuated influenza vaccine production Chin J Microbiol Immunol 2015 35 281 285 10.3760/cma.j.issn.0254-5101.2015.04.009,https://www.researchgate.net/publication/282376333_Analysis_of_the_genetic_stability_of_the_master_virus_seeds_for_live_attenuated_influenza_vaccine_productionOpen DOISearch in Google Scholar

29Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatulin A.I., Shcheblyakov D.V., Dzharullaeva A.S., Grousova D.M., Erokhova A.S., Kovyrshina A.V., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Lubenets N.L., Egorova D.A., Shmarov M.M., Nikitenko N.A., Morozova L.F., Smolyarchuk E.A., Kryukov E.V., Babira V.F., Borisevich S.V., Naroditsky B.S., Gintsburg A.L.: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020, 26, 396, 887–897, doi: 10.1016/S0140-6736(20)31866-3. Logunov D.Y. Dolzhikova I.V. Zubkova O.V. Tukhvatulin A.I. Shcheblyakov D.V. Dzharullaeva A.S. Grousova D.M. Erokhova A.S. Kovyrshina A.V. Botikov A.G. Izhaeva F.M. Popova O. Ozharovskaya T.A. Esmagambetov I.B. Favorskaya I.A. Zrelkin D.I. Voronina D.V. Shcherbinin D.N. Semikhin A.S. Simakova Y.V. Tokarskaya E.A. Lubenets N.L. Egorova D.A. Shmarov M.M. Nikitenko N.A. Morozova L.F. Smolyarchuk E.A. Kryukov E.V. Babira V.F. Borisevich S.V. Naroditsky B.S. Gintsburg A.L. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Lancet 2020 26 396 887–897 10.1016/S0140-6736(20)31866-3Open DOISearch in Google Scholar

30Loomis R.J., Johnson P.R.: Emerging Vaccine Technologies. Vaccines 2015, 3, 429–447, doi: 10.3390/vaccines3020429. Loomis R.J. Johnson P.R. Emerging Vaccine Technologies Vaccines 2015 3 429 447 10.3390/vaccines3020429449435326343196Open DOISearch in Google Scholar

31Luciani F.: High-throughput sequencing and vaccine design. Rev Sci Tech 2016, 35, 53–65, doi: 10.20506/rst.35.1.2417. Luciani F. High-throughput sequencing and vaccine design Rev Sci Tech 2016 35 53 65 10.20506/rst.35.1.241727217168Open DOISearch in Google Scholar

32Maniecka M.: Metody sekwencjonowania DNA (DNA sequencing methods – in Polish). http://laboratoria.net/artykul/12972.html,https://docplayer.pl/59379591-Tytul-metody-sekwencjonowania-dna-autor-magdalena-maniecka-data-publikacji.html Maniecka M. Metody sekwencjonowania DNA (DNA sequencing methods – in Polish) http://laboratoria.net/artykul/12972.html,https://docplayer.pl/59379591-Tytul-metody-sekwencjonowania-dna-autor-magdalena-maniecka-data-publikacji.htmlSearch in Google Scholar

33Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., Berka J., Braverman M.S., Chen Y.-J., Chen Z., Dewell S.B., Du L., Fierro J.M., Gomes X.V., Godwin B.C., He W., Helgesen S., Ho C.H., Irzyk G.P., Jando S.C., Alenquer M.L., Jarvie T.P., Jirage K.B., Kim J.-B., Knight J.R., Lanza J.R., Leamon J.H., Lefkowitz S.M., Lei M., Li J., Lohman K.L., Lu H., Makhijani V.B., McDade K.E., McKenna M.P., Myers E.W., Nickerson E., Nobile J.R., Plant R., Puc B.P., Ronan M.T., Roth G.T., Sarkis G.J., Simons J.F., Simpson J.W., Srinivasan M., Tartaro K.R., Tomasz A., Vogt K.A., Volkmer G.A., Wang S.H., Wang Y., Weiner M.P., Yu P., Begley R.F., Rothberg J.M.: Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437, 376–380, doi: 10.1038/nature03959. Margulies M. Egholm M. Altman W.E. Attiya S. Bader J.S. Bemben L.A. Berka J. Braverman M.S. Chen Y.-J. Chen Z. Dewell S.B. Du L. Fierro J.M. Gomes X.V. Godwin B.C. He W. Helgesen S. Ho C.H. Irzyk G.P. Jando S.C. Alenquer M.L. Jarvie T.P. Jirage K.B. Kim J.-B. Knight J.R. Lanza J.R. Leamon J.H. Lefkowitz S.M. Lei M. Li J. Lohman K.L. Lu H. Makhijani V.B. McDade K.E. McKenna M.P. Myers E.W. Nickerson E. Nobile J.R. Plant R. Puc B.P. Ronan M.T. Roth G.T. Sarkis G.J. Simons J.F. Simpson J.W. Srinivasan M. Tartaro K.R. Tomasz A. Vogt K.A. Volkmer G.A. Wang S.H. Wang Y. Weiner M.P. Yu P. Begley R.F. Rothberg J.M. Genome sequencing in microfabricated high-density picolitre reactors Nature 2005 437 376 380 10.1038/nature03959146442716056220Open DOISearch in Google Scholar

34Mee E.T., Preston M.D., Minor P.D., Schepelmann S.: Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing. Vaccine 2016, 17, 2035–2043, doi: 10.1016/j.vaccine.2015.12.020. Mee E.T. Preston M.D. Minor P.D. Schepelmann S. Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing Vaccine 2016 17 2035 2043 10.1016/j.vaccine.2015.12.020482330026709640Open DOISearch in Google Scholar

35Montmayeur A.M., Ng T.F., Schmidt A., Zhao K., Magaña L., Iber J., Castro C.J., Chen Q., Henderson E., Ramos E., Shaw J., Tatusov R.L., Dybdahl-Sissoko N., Endegue-Zanga M.C., Adeniji J.A., Oberste M.S., Burns C.C.: High-Throughput Next-Generation Sequencing of Polioviruses. J Clin Microbiol 2017, 55, 2, 606–615, doi: 10.1128/JCM.02121-16. Montmayeur A.M. Ng T.F. Schmidt A. Zhao K. Magaña L. Iber J. Castro C.J. Chen Q. Henderson E. Ramos E. Shaw J. Tatusov R.L. Dybdahl-Sissoko N. Endegue-Zanga M.C. Adeniji J.A. Oberste M.S. Burns C.C. High-Throughput Next-Generation Sequencing of Polioviruses J Clin Microbiol 2017 55 2 606–615 10.1128/JCM.02121-16527753127927929Open DOISearch in Google Scholar

36Nentwich M.M., Rudolph G.: Hereditary retinal eye diseases in childhood and youth affecting the central retina. Oman J Ophthalmol 2013, 6, 18–25, doi: 10.4103/0974-620X.122290. Nentwich M.M. Rudolph G. Hereditary retinal eye diseases in childhood and youth affecting the central retina Oman J Ophthalmol 2013 6 18 25 10.4103/0974-620X.122290387283824391367Open DOISearch in Google Scholar

37Prompetchara E., Ketloy C., Palaga T.: Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020, 38, 1–9, doi: 10.12932/AP-200220-0772. Prompetchara E. Ketloy C. Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic Asian Pac J Allergy Immunol 2020 38 1 9 10.12932/AP-200220-077232105090Open DOISearch in Google Scholar

38Raeven R.H.M., van Riet E., Meiring H.D., Metz B., Kersten G.F.A.: Systems vaccinology and big data in the vaccine development chain. Immunology 2019, 156, 33–46, doi: 10.1111/imm.13012. Raeven R.H.M. van Riet E. Meiring H.D. Metz B. Kersten G.F.A. Systems vaccinology and big data in the vaccine development chain Immunology 2019 156 33 46 10.1111/imm.13012628365530317555Open DOISearch in Google Scholar

39Rappuoli R.: Reverse vaccinology. Curr Opin Microbiol 2000, 3, 445–450, doi: 10.1016/S1369-5274(00)00119-3. Rappuoli R. Reverse vaccinology Curr Opin Microbiol 2000 3 445 450 10.1016/S1369-5274(00)00119-3Open DOISearch in Google Scholar

40Sanger F., Nicklen S., Coulson A.R.: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977, 74, 5463–5467, doi: 10.1073/pnas.74.12.5463. Sanger F. Nicklen S. Coulson A.R. DNA sequencing with chain-terminating inhibitors Proc Natl Acad Sci USA 1977 74 5463 5467 10.1073/pnas.74.12.5463431765271968Open DOISearch in Google Scholar

41Sarcey E., Serres A., Tindy F., Chareyre A., Ng S., Nicolas M., Vetter M., Bonnevay T., Abachin E., Mallet L.: Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing. J Virol Methods 2017, 246, 75–80, doi: 10.1016/j.jviromet.2017.04.016. Sarcey E. Serres A. Tindy F. Chareyre A. Ng S. Nicolas M. Vetter M. Bonnevay T. Abachin E. Mallet L. Quantifying low-frequency revertants in oral poliovirus vaccine using next generation sequencing J Virol Methods 2017 246 75 80 10.1016/j.jviromet.2017.04.01628456668Open DOISearch in Google Scholar

42Sette A., Rappuoli R.: Reverse Vaccinology: Developing Vaccines in the Era of Genomics. Immunity. 2010, 33, 530–541, doi: 10.1016/j.immuni.2010.09.017. Sette A. Rappuoli R. Reverse Vaccinology: Developing Vaccines in the Era of Genomics Immunity 2010 33 530 541 10.1016/j.immuni.2010.09.017332074221029963Open DOISearch in Google Scholar

43Shen L., Niu J., Wang C., Huang B., Wang W., Zhu N., Deng Y., Wang H., Ye F., Cen S., Tan W.: High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol 2019, 93, e00023-19, doi: 10.1128/JVI.00023. Shen L. Niu J. Wang C. Huang B. Wang W. Zhu N. Deng Y. Wang H. Ye F. Cen S. Tan W. High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses J Virol 2019 93 e00023 19 10.1128/JVI.00023Open DOISearch in Google Scholar

44Shendure J., Porreca G.J., Reppas N.B., Lin X., McCutcheon J.P., Rosenbaum A.M., Wang M.D., Zhang K., Mitra R.D., Church G.M.: Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005, 309, 1728–1732, doi: 10.1126/science.1117389. Shendure J. Porreca G.J. Reppas N.B. Lin X. McCutcheon J.P. Rosenbaum A.M. Wang M.D. Zhang K. Mitra R.D. Church G.M. Accurate multiplex polony sequencing of an evolved bacterial genome Science 2005 309 1728 1732 10.1126/science.111738916081699Open DOISearch in Google Scholar

45Spatz S.J.: Accumulation of attenuating mutations in varying proportions within a high passage very virulent plus strain of Gallid herpesvirus type 2. Virus Res 2010, 149, 135–142, doi: 10.1016/j.virusres.2010.01.007. Spatz S.J. Accumulation of attenuating mutations in varying proportions within a high passage very virulent plus strain of Gallid herpesvirus type 2 Virus Res 2010 149 135 142 10.1016/j.virusres.2010.01.00720109506Open DOISearch in Google Scholar

46Sugawara H., Ogasawara O., Okubo K., Gojobori T., Tateno Y.: Nucleic Acids Res. 2008, 36 (Database issue), D22–D24, doi: 10.1093/nar/gkm889. Sugawara H. Ogasawara O. Okubo K. Gojobori T. Tateno Y. Nucleic Acids Res 2008 36 Database issue D22 D24 10.1093/nar/gkm889223882917962300Open DOISearch in Google Scholar

47Urrutia-Baca V.H., Gomez-Flores R., De La Garza-Ramos M.A., Tamez-Guerra P., Lucio-Sauceda D.G., Rodríguez-Padilla M.C.: Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori. J Comput Biol 2019, 26, 1177–1190, doi: 10.1089/cmb.2019.0062. Urrutia-Baca V.H. Gomez-Flores R. De La Garza-Ramos M.A. Tamez-Guerra P. Lucio-Sauceda D.G. Rodríguez-Padilla M.C. Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori J Comput Biol 2019 26 1177 1190 10.1089/cmb.2019.0062678634531120321Open DOISearch in Google Scholar

48Zeb S., Ali A., Gulfam S.M., Bokhari H.: Preliminary Work Towards Finding Proteins as Potential Vaccine Candidates for Vibrio cholerae Pakistani Isolates through Reverse Vaccinology. Medicina 2019, 55, 195, doi: 10.3390/medicina55050195. Zeb S. Ali A. Gulfam S.M. Bokhari H. Preliminary Work Towards Finding Proteins as Potential Vaccine Candidates for Vibrio cholerae Pakistani Isolates through Reverse Vaccinology Medicina 2019 55 195 10.3390/medicina55050195657189031126058Open DOISearch in Google Scholar

49Zhu F.-C., Li Y.-H., Guan X.-H., Hou L.-H., Wang W.-J., Li J.-X., Wu S.-P., Wang B.-S., Wang Z., Wang L., Jia S.-Y., Jiang H.-D., Wang L., Jiang T., Hu Y., Gou J.-B., Xu S.-B., Xu J.-J., Wang X.-W., Wang W., Chen W.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020, 395, 1845–1854, doi: 10.1016/S0140-6736(20)31208-3. Zhu F.-C. Li Y.-H. Guan X.-H. Hou L.-H. Wang W.-J. Li J.-X. Wu S.-P. Wang B.-S. Wang Z. Wang L. Jia S.-Y. Jiang H.-D. Wang L. Jiang T. Hu Y. Gou J.-B. Xu S.-B. Xu J.-J. Wang X.-W. Wang W. Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet 2020 395 1845 1854 10.1016/S0140-6736(20)31208-3Open DOISearch in Google Scholar